-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-12-23
Values as of: 2024-12-23
The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Pharmaceutical IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 23 U.S. pharmaceuticals companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Company Website : www.invescopowershares.com
Currency: USD
Country : USA
Inception Date: 23/06/2005
Primary Benchmark: Dynamic Pharmaceutical Intellidex TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.57%
Management Expense Ratio: 0.56 %
N/A
N/A
| Symbol | Company Name | Allocation |
|---|---|---|
| TARS | Tarsus Pharmaceuticals Inc | 3.07 % |
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| XLV | Health Care Select Sector SPDR.. | 0.13 % |
+0.75 (+0.54%) |
USD 36.67B |
| FHLC | Fidelity® MSCI Health Care In.. | 0.08 % |
+0.65 (+0.99%) |
USD 2.62B |
| FXH | First Trust Health Care AlphaD.. | 0.63 % |
+0.16 (+0.15%) |
USD 1.09B |
| BBH | VanEck Biotech ETF | 0.35 % |
-0.25 (-0.16%) |
USD 0.42B |
| XHE | SPDR® S&P Health Care Equipme.. | 0.35 % |
-0.26 (-0.29%) |
USD 0.21B |
| IDNA | iShares Genomics Immunology an.. | 0.00 % |
+0.15 (+0.66%) |
USD 0.12B |
| SBIO | ALPS Medical Breakthroughs ETF | 0.50 % |
-0.01 (-0.03%) |
USD 0.11B |
| XHS | SPDR® S&P Health Care Service.. | 0.35 % |
-0.09 (-0.10%) |
USD 0.07B |
| HTEC | Robo Global® Healthcare Techn.. | 0.00 % |
+0.09 (+0.29%) |
USD 0.05B |
| BBP | Virtus LifeSci Biotech Product.. | 0.79 % |
+0.23 (+0.38%) |
USD 0.02B |
N/A
| Market Performance vs. Industry/Classification (Health) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 9.28% | 100% | F | 61% | D- | ||
| Dividend Return | 0.76% | 53% | F | 9% | A- | ||
| Total Return | 10.04% | 100% | F | 55% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 10.21% | 100% | F | 63% | D | ||
| Dividend Return | 0.77% | 53% | F | 9% | A- | ||
| Total Return | 10.97% | 100% | F | 57% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 26.58% | 73% | C | 64% | D | ||
| Dividend Return | 5.02% | 60% | D- | 13% | F | ||
| Total Return | 31.59% | 64% | D | 57% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 7.23% | 81% | B- | 58% | F | ||
| Dividend Return | 7.82% | 81% | B- | 53% | F | ||
| Total Return | 0.58% | 58% | F | 15% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 13.36% | 76% | C+ | 71% | C- | ||
| Risk Adjusted Return | 58.50% | 86% | B+ | 73% | C | ||
| Market Capitalization | 0.91B | N/A | N/A | N/A | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
There is nothing we particularly dislike
